Catalyst
Slingshot members are tracking this event:
Sage Therapeutics' (SAGE) Lead Candidate SAGE-547 for Postpartum Depression (PPD) Granted Priority Medicines (PRIME) Designation by European Medicines Agency (EMA)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SAGE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 16, 2016
Related Projects
- Digesting the significance of SAGE-547's success in its Phase 2 postpartum depression study SAGE Executed On: Jul 29, 2016 at 12:45 PM EDT
Related Keywords
Lead Candidate, Sage-547, Postpartum Depression, Ppd, Priority Medicines Designation, Prime Status, European Medicines Agency, Ema
